Peptide Therapeutics Market by Type, Type of Manufacturers, Route of Administration, Application & Technology - Global Industry Analysis and Forecast to 2023

Published On : April 2018 Pages : 120 Category: Pharmaceuticals Report Code : HC04678

Industry Outlook and Trend Analysis

The Peptide Therapeutics Market was worth USD 19.52 billion in 2014 and is expected to reach approximately USD 42.97 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 9.16% during the forecast period. Expanding prevalence of cancer and metabolic disorders, for example, obesity, diabetes, and osteoporosis are the key variables contributing toward the adoption of peptide therapeutics over the conjecture time frame. The demand for low-cost and efficient drugs is high because of developing base of affected paediatric populace and predominance of target diseases in countries with a low income. The development is specifically connected with rising interests in drug revelation.

Application Outlook and Trend Analysis

The cancer section ruled in 2016 with revenue share of over USD 1.85 billion. Expanding prevalence of cancer worldwide and expanding prescription of peptide therapeutics for malignancy treatment are the key components in charge of predominance in this fragment. Rising demand for rapid-acting and efficient therapeutics is foreseen to highlight development.

Type Outlook and Trend Analysis

The innovative peptides ruled in 2016 and held a share of around 66.93%, inferable from the expanding ventures by vast pharmaceuticals in R&D for the improvement of novel drugs and high prescription rate. Nonetheless, generics are expected to encounter lucrative growth over the conjecture time frame.

Manufacturing type Outlook and Trend Analysis

The in-house manufacturing section held the biggest share representing more than 60.0% in 2016. Majority of the key players are engaged with developing peptide therapeutics in-house attributable to stringent regulations and increasing expenses of outsourcing. As huge pharmaceutical organizations have legitimate infrastructure for large-scale manufacturing and advanced technology, these organizations favour in-house manufacturing.

Route of administration Outlook and Trend Analysis

The biopharmaceuticals giants are constantly examining new techniques for drug delivery suitable to peptides. Novel drug delivery technologies are presently being evaluated for efficacy with engineered molecules containing advanced PEGylation, trying to enhance performance of drug delivery performance through better methods of drug delivery.  Parenteral course of administration commanded in 2016 with a significant share of the market.

Synthesis Technology Outlook and Trend Analysis

The LPPS section ruled with share of more than 45.0% in 2016 attributable to existence of growing demand for unadulterated peptides for improvement of effective therapeutics. Nonetheless, issues, for example, higher usage of time are in charge of switching preferences of consumers to effective and faster methods, for example, SPPS.

Regional Outlook and Trend Analysis

North America commanded the market in 2016. Increasing awareness levels relating to peptide therapeutics products, expanding interest for diagnostics in cancer and other diseases, and developing biotechnology sector are the components contributing toward the strength. Expanding R&D expenditure by government is additionally assessed to enable peptide therapeutics to keep up predominance over the coming years.

Competitive Insights

The leading players in the market are Sanofi, Lonza Group, GlaxoSmithKline, Pfizer, Eli Lilly and Company, Novo Nordisk, Teva Pharmaceutical Industries, Novartis, Takeda Pharmaceutical Company, Bristol-Myers Squibb, AstraZeneca and Amgen. Improvement of new products and adopting technological progressions are key methods attempted by the organizations to maintain market position. In addition, expanding collaborations for undertaking trials of new drugs is evaluated to increment competition.

The Peptide Therapeutics Market is segmented as follows-

By Application:

  • Metabolic
  • Respiratory
  • Anti-infection
  • Dermatology
  • Renal
  • Cancers
  • Cardiovascular Disorder
  • GIT
  • Pain
  • CNS
  • Others

By Type:

  • Innovative
  • Generic

By Type of Manufacturers:

  • Outsourced
  • In-house

By Route of Administration:

  • Oral Route
  • Mucosal
  • Parenteral Route
  • Pulmonary
  • Others

By Synthesis Technology:

  • Liquid Phase Peptide Synthesis (LPPS)
  • Solid Phase Peptide Synthesis (SPPS)
  • Hybrid Technology

By Region

  • North America
    • U.S.
    • Canada
    • Mexico

 

  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe

 

  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific

 

  • South America
    • Brazil
    • Argentina
    • Columbia
    • South Africa
    • Rest of South America

 

  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Some of the key questions answered by the report are:

  • What was the market size in 2014 and forecast from 2015 to 2023?
  • What will be the industry market growth from 2015 to 2023?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

·         Peptide Therapeutics Market, By Type, Estimates and Forecast, 2014-2023 ($Million)

o    Generic

o    Innovative

·         Peptide Therapeutics Market, By Type of Manufacturers, Estimates and Forecast, 2014-2023 ($Million)

o    In-house

o    Outsourced

·         Peptide Therapeutics Market, By Route of Administration, Estimates and Forecast, 2014-2023 ($Million)

o    Parenteral Route

o    Oral Route

o    Pulmonary

o    Mucosal

o    Other Route of Administrations

·         Peptide Therapeutics Market, By Application, Estimates and Forecast, 2014-2023 ($Million)

o    Cancers

o    Metabolic

o    Cardiovascular Disorder

o    Respiratory

o    GIT

o    Anti-infection

o    Pain

o    Dermatology

o    CNS

o    Renal

o    Other Applications

·         Peptide Therapeutics Market, By Technology, Estimates and Forecast, 2014-2023 ($Million)

o    Solid Phase Peptide Synthesis (SPPS)

o    Liquid Phase Peptide Synthesis (LPPS)

o    Hybrid Technology

·         Peptide Therapeutics Market, By Region, Estimates and Forecast, 2014-2023 ($Million)

o    North America

§  North America Peptide Therapeutics Market, By Country

o    U.S. Peptide Therapeutics Market

o    Canada Peptide Therapeutics Market

o    Mexico Peptide Therapeutics Market

o    Europe

§  Europe Peptide Therapeutics Market, By Country

o    Germany Peptide Therapeutics Market

o    UK Peptide Therapeutics Market

o    France Peptide Therapeutics Market

o    Russia Peptide Therapeutics Market

o    Italy Peptide Therapeutics Market

o    Rest of Europe Peptide Therapeutics Market

o    Asia-Pacific

§  Asia-Pacific Peptide Therapeutics Market, By Country

o    China Peptide Therapeutics Market

o    Japan Peptide Therapeutics Market

o    South Korea Peptide Therapeutics Market

o    India Peptide Therapeutics Market

o    Southeast Asia Peptide Therapeutics Market

o    Rest of Asia-Pacific Peptide Therapeutics Market

o    South America

§  South America Peptide Therapeutics Market

o    Brazil Peptide Therapeutics Market

o    Argentina Peptide Therapeutics Market

o    Columbia Peptide Therapeutics Market

o    South Africa Peptide Therapeutics Market

o    Rest of South America Peptide Therapeutics Market

o    Middle East and Africa

§  Middle East and Africa Peptide Therapeutics Market

o    Saudi Arabia Peptide Therapeutics Market

o    UAE Peptide Therapeutics Market

o    Egypt Peptide Therapeutics Market

o    Nigeria Peptide Therapeutics Market

o    South Africa Peptide Therapeutics Market

o    Rest of MEA Peptide Therapeutics Market

Table of Contents

1.       Introduction

1.1.       Report Description

1.2.       Research Methodology

1.2.1.  Secondary Research

1.2.2.  Primary Research

2.       Executive Summary

2.1.       Key Highlights

3.       Market Overview

3.1.       Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.       Market Dynamics

3.2.1.  Drivers

3.2.1.1.    Rising Incidences of Metabolic Disorder

3.2.1.2.    Presence of Strong Product Pipeline Portfolio

3.2.2.  Restraints

3.2.2.1.    Stringent Regulations

3.2.3.  Opportunities

3.2.3.1.    Emerging Markets to Offer Lucrative Growth Opportunities

4.       Market Analysis by Regions

4.1.       North America (United States, Canada and Mexico)

4.1.1.  United States Market States and Outlook (2014-2023)

4.1.2.  Canada Market States and Outlook (2014-2023)

4.1.3.  Mexico Market States and Outlook (2014-2023)

4.2.       Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market States and Outlook (2014-2023)

4.2.2.  France Market States and Outlook (2014-2023)

4.2.3.  UK Market States and Outlook (2014-2023)

4.2.4.  Russia Market States and Outlook (2014-2023)

4.2.5.  Italy Market States and Outlook (2014-2023)

4.2.6.  Rest of Europe Market States and Outlook (2014-2023)

4.3.       Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market States and Outlook (2014-2023)

4.3.2.  Japan Market States and Outlook (2014-2023)

4.3.3.  Korea Market States and Outlook (2014-2023)

4.3.4.  India Market States and Outlook (2014-2023)

4.3.5.  Rest of Asia-Pacific Market States and Outlook (2014-2023)

4.4.       South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market States and Outlook (2014-2023)

4.4.2.  Argentina Market States and Outlook (2014-2023)

4.4.3.  Columbia Market States and Outlook (2014-2023)

4.4.4.  Rest of South America Market States and Outlook (2014-2023)

4.5.       Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market States and Outlook (2014-2023)

4.5.2.  UAE Market States and Outlook (2014-2023)

4.5.3.  Egypt Market States and Outlook (2014-2023)

4.5.4.  Nigeria Market States and Outlook (2014-2023)

4.5.5.  South Africa Market States and Outlook (2014-2023)

4.5.6.  Rest of MEA Market States and Outlook (2014-2023)

5.       Peptide Therapeutics Market, By Type

5.1.       Introduction

5.2.       Global Peptide Therapeutics Sales, Revenue and Market Share by Type (2014-2018)

5.2.1.  Global Peptide Therapeutics Sales and Sales Share by Type (2014-2018)

5.2.2.  Global Peptide Therapeutics Revenue and Revenue Share by Type (2014-2018)

5.3.       Generic

5.3.1.  Global Generic Sales and Growth Rate (2014-2018)

5.4.       Innovative

5.4.1.  Global Innovative Sales and Growth Rate (2014-2018)

6.       Peptide Therapeutics Market, By Application

6.1.       Introduction

6.2.       Global Peptide Therapeutics Sales, Revenue and Market Share by Application (2014-2018)

6.2.1.  Global Peptide Therapeutics Sales and Sales Share by Application (2014-2018)

6.2.2.  Global Peptide Therapeutics Revenue and Revenue Share by Application (2014-2018)

6.3.       Cancers

6.3.1.  Global Cancers Sales and Growth Rate (2014-2018)

6.4.       Metabolic

6.4.1.  Global Metabolic Sales and Growth Rate (2014-2018)

6.5.       Cardiovascular Disorder

6.5.1.  Global Cardiovascular Disorder Sales and Growth Rate (2014-2018)

6.6.       Respiratory

6.6.1.  Global Respiratory Sales and Growth Rate (2014-2018)

6.7.       GIT

6.7.1.  Global GIT Sales and Growth Rate (2014-2018)

6.8.       Anti-infection

6.8.1.  Global Anti-infection Sales and Growth Rate (2014-2018)

6.9.       Pain

6.9.1.  Global Pain Sales and Growth Rate (2014-2018)

6.10.    Dermatology

6.10.1.      Global Dermatology Sales and Growth Rate (2014-2018)

6.11.    CNS

6.11.1.      Global CNS Sales and Growth Rate (2014-2018)

6.12.    Renal

6.12.1.      Global Renal Sales and Growth Rate (2014-2018)

6.13.    Other Applications

6.13.1.      Global Other Applications Sales and Growth Rate (2014-2018)

7.       Peptide Therapeutics Market, By Type Of Manufacturers

7.1.       Introduction

7.2.       Global Peptide Therapeutics Sales, Revenue and Market Share by Type Of Manufacturers (2014-2018)

7.2.1.  Global Peptide Therapeutics Sales and Sales Share by Type Of Manufacturers (2014-2018)

7.2.2.  Global Peptide Therapeutics Revenue and Revenue Share by Type Of Manufacturers (2014-2018)

7.3.       In-house

7.3.1.  Global In-house Sales and Growth Rate (2014-2018)

7.4.       Outsourced

7.4.1.  Global Outsourced Sales and Growth Rate (2014-2018)

8.       Peptide Therapeutics Market, By Route of Administration

8.1.       Introduction

8.2.       Global Peptide Therapeutics Sales, Revenue and Market Share by Route of Administration (2014-2018)

8.2.1.  Global Peptide Therapeutics Sales and Sales Share by Route of Administration (2014-2018)

8.2.2.  Global Peptide Therapeutics Revenue and Revenue Share by Route of Administration (2014-2018)

8.3.       Parenteral Route

8.3.1.  Global Parenteral Route Sales and Growth Rate (2014-2018)

8.4.       Oral Route

8.4.1.  Global Oral Route Sales and Growth Rate (2014-2018)

8.5.       Pulmonary

8.5.1.  Global Pulmonary Sales and Growth Rate (2014-2018)

8.6.       Mucosal

8.6.1.  Global Mucosal Sales and Growth Rate (2014-2018)

8.7.       Other Route of Administrations

8.7.1.  Global Other Route of Administrations Sales and Growth Rate (2014-2018)

9.       Peptide Therapeutics Market, By Technology

9.1.       Introduction

9.2.       Global Peptide Therapeutics Sales, Revenue and Market Share by Technology (2014-2018)

9.2.1.  Global Peptide Therapeutics Sales and Sales Share by Technology (2014-2018)

9.2.2.  Global Peptide Therapeutics Revenue and Revenue Share by Technology (2014-2018)

9.3.       Solid Phase Peptide Synthesis (SPPS)

9.3.1.  Global Solid Phase Peptide Synthesis (SPPS) Sales and Growth Rate (2014-2018)

9.4.       Liquid Phase Peptide Synthesis (LPPS)

9.4.1.  Global Liquid Phase Peptide Synthesis (LPPS) Sales and Growth Rate (2014-2018)

9.5.       Hybrid Technology

9.5.1.  Global Hybrid Technology Sales and Growth Rate (2014-2018)

10.   Peptide Therapeutics Market, By Region

10.1.    Introduction

10.2.    Global Peptide Therapeutics Sales, Revenue and Market Share by Regions

10.2.1.      Global Peptide Therapeutics Sales by Regions (2014-2018)

10.2.2.      Global Peptide Therapeutics Revenue by Regions (2014-2018)

10.3.    North America Peptide Therapeutics by Countries

10.3.1.      North America Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.3.2.      North America Peptide Therapeutics Revenue and Growth Rate (2014-2018)

10.3.3.      North America Peptide Therapeutics Sales by Countries (2014-2018)

10.3.4.      North America Peptide Therapeutics Revenue (Million USD) by Countries (2014-2018)

10.3.5.      U.S.

10.3.5.1. United States Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.3.5.2. United States Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.3.6.      Canada

10.3.6.1. Canada Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.3.6.2. Canada Peptide Therapeutics Sales (Millions USD) and Growth Rate (2014-2018)

10.3.7.      Mexico

10.3.7.1. Mexico Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.3.7.2. Mexico Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.4.    Europe Peptide Therapeutics by Countries

10.4.1.      Europe Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.4.2.      Europe Peptide Therapeutics Revenue and Growth Rate (2014-2018)

10.4.3.      Europe Peptide Therapeutics Sales by Countries (2014-2018)

10.4.4.      Europe Peptide Therapeutics Revenue (Million USD) by Countries (2014-2018)

10.4.5.      Germany

10.4.5.1. Germany Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.4.5.2. Germany Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.4.6.      UK

10.4.6.1. UK Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.4.6.2. UK Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.4.7.      France

10.4.7.1. France Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.4.7.2. France Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.4.8.      Russia

10.4.8.1. Russia Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.4.8.2. Russia Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.4.9.      Italy

10.4.9.1. Italy Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.4.9.2. Italy Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.4.10.  Rest of Europe

10.4.10.1.              Rest of Europe Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.4.10.2.              Rest of Europe Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.5.    Asia-Pacific

10.5.1.      Asia-Pacific Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.5.2.      Asia-Pacific Peptide Therapeutics Revenue and Growth Rate (2014-2018)

10.5.3.      Asia-Pacific Peptide Therapeutics Sales by Countries (2014-2018)

10.5.4.      Asia-Pacific Peptide Therapeutics Revenue (Million USD) by Countries (2014-2018)

10.5.5.      China

10.5.5.1. China Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.5.5.2. China Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.5.6.      Japan

10.5.6.1. Japan Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.5.6.2. Japan Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.5.6.3.  

10.5.7.      Korea

10.5.7.1. Korea Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.5.7.2. Korea Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.5.8.      India

10.5.8.1. India Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.5.8.2. India Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.5.9.      Southeast Asia

10.5.9.1. Southeast Asia Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.5.9.2. Southeast Asia Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.5.10.  Rest of Asia-Pacific

10.5.10.1.              Rest of Asia-Pacific Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.5.10.2.              Rest of Asia-Pacific Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.6.    South America

10.6.1.      South America Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.6.2.      South America Peptide Therapeutics Revenue and Growth Rate (2014-2018)

10.6.3.      South America Peptide Therapeutics Sales by Countries (2014-2018)

10.6.4.      South America Peptide Therapeutics Revenue (Million USD) by Countries (2014-2018)

10.6.5.      Brazil

10.6.5.1. Brazil Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.6.5.2. Brazil Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.6.6.      Argentina

10.6.6.1. Argentina Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.6.6.2. Argentina Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.6.7.      Columbia

10.6.7.1. Columbia Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.6.7.2. Columbia Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.6.8.      Rest of South America

10.6.8.1. Rest of South America Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.6.8.2. Rest of South America Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.7.    Middle East and Africa

10.7.1.      Middle East and Africa Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.7.2.      Middle East and Africa Peptide Therapeutics Revenue and Growth Rate (2014-2018)

10.7.3.      Middle East and Africa Peptide Therapeutics Sales by Countries (2014-2018)

10.7.4.      Middle East and Africa Peptide Therapeutics Revenue (Million USD) by Countries (2014-2018)

10.7.5.      Saudi Arabia

10.7.5.1. Saudi Arabia Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.7.5.2. Saudi Arabia Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.7.6.      United Arab Emirates

10.7.6.1. United Arab Emirates Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.7.6.2. United Arab Emirates Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.7.7.      Egypt

10.7.7.1. Egypt Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.7.7.2. Egypt Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.7.8.      Nigeria

10.7.8.1. Nigeria Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.7.8.2. Nigeria Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.7.9.      South Africa

10.7.9.1. South Africa Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.7.9.2. South Africa Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

10.7.10.  Rest of Middle East and Africa

10.7.10.1.              Rest of Middle East and Africa Peptide Therapeutics Sales and Growth Rate (2014-2018)

10.7.10.2.              Rest of Middle East and Africa Peptide Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

11.   Company Profiles

11.1.      Bachem Holding AG

11.1.1.      Business Overview

11.1.2.      Product Portfolio

11.1.3.      Strategic Developments

11.1.4.      Sales, Revenue and Market Share

11.2.    Eli Lilly and Company

11.2.1.      Business Overview

11.2.2.      Product Portfolio

11.2.3.      Strategic Developments

11.2.4.      Sales, Revenue and Market Share

11.3.    Pfizer Inc.

11.3.1.      Business Overview

11.3.2.      Product Portfolio

11.3.3.      Strategic Developments

11.3.4.      Sales, Revenue and Market Share

11.4.    Amgen Inc.

11.4.1.      Business Overview

11.4.2.      Product Portfolio

11.4.3.      Strategic Developments

11.4.4.      Sales, Revenue and Market Share

11.5.    Takeda Pharmaceutical Company Limited

11.5.1.      Business Overview

11.5.2.      Product Portfolio

11.5.3.      Strategic Developments

11.5.4.      Sales, Revenue and Market Share

11.6.    Teva Pharmaceutical

11.6.1.      Business Overview

11.6.2.      Product Portfolio

11.6.3.      Strategic Developments

11.6.4.      Sales, Revenue and Market Share

11.7.     Lonza Inc.

11.7.1.      Business Overview

11.7.2.      Product Portfolio

11.7.3.      Strategic Developments

11.7.4.      Sales, Revenue and Market Share

11.8.    Sanofi

11.8.1.      Business Overview

11.8.2.      Product Portfolio

11.8.3.      Strategic Developments

11.8.4.      Sales, Revenue and Market Share

11.9.    Bristol-Myers Squibb(BMS)

11.9.1.      Business Overview

11.9.2.      Product Portfolio

11.9.3.      Strategic Developments

11.9.4.      Sales, Revenue and Market Share

11.10.AstraZeneca PLC

11.10.1.  Business Overview

11.10.2.  Product Portfolio

11.10.3.  Strategic Developments

11.10.4.  Sales, Revenue and Market Share

12.   Global Peptide Therapeutics Market Competition, by Manufacturer

12.1.    Global Peptide Therapeutics Sales and Market Share by Manufacturer (2016-2017)

12.2.    Global Peptide Therapeutics Revenue and Market Share by Manufacturer (2016-2017)

12.3.    Global Peptide Therapeutics Price by Manufacturer (2016-2017)

12.4.    Top 5 Peptide Therapeutics Manufacturer Market Share

12.5.    Market Competition Trend

13.   Peptide Therapeutics Market Forecast (2018-2023)

13.1.    Global Peptide Therapeutics Sales, Revenue (Millions USD) and Growth Rate (2018-2023)

13.2.    Peptide Therapeutics Market Forecast by Regions (2018-2023)

13.2.1.      North America Peptide Therapeutics Market Forecast (2018-2023)

13.2.1.1. United States Peptide Therapeutics Market Forecast (2018-2023)

13.2.1.2. Canada Peptide Therapeutics Market Forecast (2018-2023)

13.2.1.3. Mexico Peptide Therapeutics Market Forecast (2018-2023)

13.2.2.      Europe Peptide Therapeutics Market Forecast (2018-2023)

13.2.2.1. Germany Peptide Therapeutics Market Forecast (2018-2023)

13.2.2.2. United Kingdom Peptide Therapeuticss Market Forecast (2018-2023)

13.2.2.3. France Peptide Therapeutics Market Forecast (2018-2023)

13.2.2.4. Russia Peptide Therapeutics Market Forecast (2018-2023)

13.2.2.5. Italy Peptide Therapeutics Market Forecast (2018-2023)

13.2.2.6. Rest of the Europe Peptide Therapeutics Market Forecast (2018-2023)

13.2.3.      Asia-Pacific Peptide Therapeutics Market Forecast (2018-2023)

13.2.3.1. China Peptide Therapeutics Market Forecast (2018-2023)

13.2.3.2. Japan Peptide Therapeutics Market Forecast (2018-2023)

13.2.3.3. Korea Peptide Therapeutics Market Forecast (2018-2023)

13.2.3.4. India Peptide Therapeutics Market Forecast (2018-2023)

13.2.3.5. Southeast Asia Peptide Therapeutics Market Forecast (2018-2023)

13.2.3.6. Rest of Asia-Pacific Peptide Therapeutics Market Forecast (2018-2023)

13.2.4.      South America Peptide Therapeutics Market Forecast (2018-2023)

13.2.4.1. Brazil Peptide Therapeutics Market Forecast (2018-2023)

13.2.4.2. Argentina Peptide Therapeutics Market Forecast (2018-2023)

13.2.4.3. Columbia Peptide Therapeutics Market Forecast (2018-2023)

13.2.4.4. Rest of South America Peptide Therapeutics Market Forecast (2018-2023)

13.2.5.      Middle East and Africa Peptide Therapeutics Market Forecast (2018-2023)

13.2.5.1. Saudi Arabia Peptide Therapeutics Market Forecast (2018-2023)

13.2.5.2. UAE Peptide Therapeutics Market Forecast (2018-2023)

13.2.5.3. Egypt Peptide Therapeutics Market Forecast (2018-2023)

13.2.5.4. Nigeria Peptide Therapeutics Market Forecast (2018-2023)

13.2.5.5. South Africa Peptide Therapeutics Market Forecast (2018-2023)

13.2.5.6. Rest of MEA Peptide Therapeutics Market Forecast (2018-2023)

13.3.    Peptide Therapeutics Market Forecast by Type (2018-2023)

13.3.1.      Global Peptide Therapeutics Sales Forecast by Type (2018-2023)

13.3.2.      Global Peptide Therapeutics Sales Market Share Forecast by Type (2018-2023)

13.4.    Peptide Therapeutics Market Forecast by Application (2018-2023)

13.4.1.      Global Peptide Therapeutics Sales Forecast by Application (2018-2023)

13.4.2.      Global Peptide Therapeutics Sales Market Share Forecast by Application (2018-2023)

13.5.    Peptide Therapeutics Market Forecast by Type Of Manufacturers (2018-2023)

13.5.1.      Global Peptide Therapeutics Sales Forecast by Type Of Manufacturers (2018-2023)

13.5.2.      Global Peptide Therapeutics Sales Market Share Forecast by Type Of Manufacturers (2018-2023)

13.6.    Peptide Therapeutics Market Forecast by Route of Administration (2018-2023)

13.6.1.      Global Peptide Therapeutics Sales Forecast by Route of Administration (2018-2023)

13.6.2.      Global Peptide Therapeutics Sales Market Share Forecast by Route of Administration (2018-2023)

13.7.    Peptide Therapeutics Market Forecast by Technology (2018-2023)

13.7.1.      Global Peptide Therapeutics Sales Forecast by Technology (2018-2023)

13.7.2.      Global Peptide Therapeutics Sales Market Share Forecast by Technology (2018-2023)


List of Tables

*You can glance through the list of Tables and Figures when you view the sample copy of Peptide Therapeutics Market.


Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources

  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources

  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)

  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*